Press Releases

Press ReleasesAIM ImmunoTech2019-04-23T08:44:59-04:00

Sep 28, 2021 AIM ImmunoTech Submits Pre-IND Application to the FDA for Phase 2 Clinical Studies of Ampligen as a Potential Early-Onset Therapeutic for COVID-19

Sep 27, 2021 AIM ImmunoTech Files Provisional Patent Application for Ampligen as an Early-Onset Intranasal Therapy that May Also Confer Enhanced Immunity to a Wide Range of Respiratory Viruses

Sep 21, 2021 AIM ImmunoTech Announces Positive Progress on Requested FDA Meeting for Proposed Ampligen Clinical Trial in Post-COVID-19 Cognitive Dysfunction

Sep 20, 2021 AIM ImmunoTech Provides an Update on Its Pending Phase 2a Human Challenge Trial Using its Drug Ampligen

Sep 08, 2021 AIM ImmunoTech Submits Pre-IND Application to the FDA for Phase 2 Clinical Study of Ampligen as a Potential Infusion Therapy for Post-COVID-19 Cognitive Dysfunction

Aug 25, 2021 AIM ImmunoTech Announces Filing of Provisional Patent Application for Use of Ampligen as Both an Intranasal and an IV Therapy for Post-COVID-19 Cognitive Dysfunction (PCCD)

Aug 17, 2021 AIM ImmunoTech Provides Second Quarter 2021 Business Update

Aug 16, 2021 AIM CEO Thomas K. Equels Named to Board of Directors of BioFlorida Inc.

Jul 09, 2021 AIM ImmunoTech Announces Phase 2a Human Challenge Trial to Test its Drug Ampligen as an Intranasal Antiviral Prophylactic Therapy

Jul 06, 2021 AIM ImmunoTech to Host Investor Update Webcast on Wednesday, July 14th at 11:00 AM ET

<< < > >>